News

TAIPEI – August 16, 2023 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TWO) announced today that the company has entered into a licensing agreement with Eyenovia, Inc. (“Eyenovia”, NASDAQ: EYEN), whereby Eyenovia obtains exclusive U.S. rights for the commercialization of APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for the treatment of inflammation and pain following ocular surgery.  APP13007 …

Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery Read More »

July 5th, 2023 TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) announce the United States Food & Drug Administration (US FDA) acceptance of its New Drug Application for APP13007, a novel aqueous nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain following ocular surgery.  The FDA has assigned a …

Formosa Pharmaceuticals Announce FDA Acceptance of NDA Filing for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery Read More »

May 5th, 2023 TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the United States Food & Drug Administration (US FDA) for APP13007, a novel aqueous nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain …

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery Read More »

February 15th, 2023 The collaboration will combine Formosa’s proprietary APNT™ nanoparticle formulation platform with Eyenovia’s Optejet® dispensing technology for the development of new ophthalmic therapies in high-value indications with significant unmet medical needs. TAIPEI – February 15, 2023 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TWO) announced today that the company has entered into a collaboration agreement …

Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia Read More »

January 31st, 2023 TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) report a summary of integrated clinical results for APP13007, a novel ophthalmic nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain after cataract surgery.  Included in the summary results are Phase 2 clinical trials (CPN-201) and two parallel …

Formosa Pharmaceuticals Announce a Summary of Integrated Clinical Results for APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery Read More »

November 8th, 2022 Taipei, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and development partner, AimMax Therapeutics, Inc. (US), announced the completion of a pre-NDA meeting with the US FDA for its lead program, APP13007, a 14-day, twice-daily eyedrop for the treatment of inflammation and pain after ocular surgery.  The favorable outcome of the meeting lays the …

Formosa Pharmaceuticals, completes successful pre-NDA Meeting with the US FDA and plans for NDA submission of APP13007 Read More »

TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-302, the second of the two pivotal Phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain after cataract surgery.  CPN-302 was …

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery. Read More »

TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel formulation of the potent corticosteroid, clobetasol propionate, for the treatment of inflammation and pain after cataract surgery, will be presented at the 2022 Association for …

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting Read More »

TAIPEI, May 12, 2022 /PRNewswire/ — Formosa Pharmaceuticals, Inc. (TWO.6838) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-301, the first of two pivotal Phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of a potent corticosteroid, clobetasol propionate(0.05%), for the treatment of inflammation and pain after cataract surgery. CPN-301 …

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery Read More »

TAIPEI, Taiwan, March 24, 2022 – Formosa Pharmaceuticals, Inc. (6838.TWO) announce the approval of a resolution by the boards of directors of both Formosa Pharmaceuticals and EirGenix, Inc. (6589.TT) for the co-development of anticancer ADC, TSY-0110 (EG12043).  This agreement strengthens the existing relationship between both companies and fortifies TSY-0110’s clinical development pathway and subsequent licensing …

Formosa Pharmaceuticals and EirGenix establish a co-development alliance to develop TSY-0110 / EG12043 (ado-trastuzumab emtansine biosimilar) for HER2-positive breast cancer. Read More »